AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04769050
Drug: T-DM1 or Capecitabine combined with Pyrotinib regimen.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-DM1, 3.6mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Capecitabine, 1250 mg/m2 bid po d1-14 q3w Pyrotinib, 400mg po daily (continuously)
Trial: NCT05609370
Drug: LBL-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously.
Trial: NCT05609370
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered in accordance with relevant local guidelines and/or prescribing information
Trial: NCT06565078
Drug: Immune Globulin Subcutaneous (Human), 20% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUVITRU 20% Solution
Trial: NCT06069102
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The usual care group will be given anti-hypertensive medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's BP consistently exceeds 150/100 mmHg consistently.
Trial: NCT06069102
Drug: Tight blood pressure control
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention group will be initiated on blood pressure medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's hospital BP consistently exceeds 140/90 mmHg or home BP consistently exceeds 135/85 mmHg.
Trial: NCT04873362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to atezolizumab will be administered at a dose of 1200 mg Q3W for 14 cycles.
Trial: NCT05126277
Drug: placebo s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo s.c. q4w in addition to SoC
Trial: NCT05944016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (standard dose p.o. once daily)
Trial: NCT05018481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo will be given in capsule form to study participants
Trial: NCT06020716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times daily
Trial: NCT03761511
Drug: Nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinamide 4 g (capsules) or highest tolerated dose with a minimum of 2 g/d per os once daily
Trial: NCT04788511
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~The study will last for approximately 59 weeks.
Trial: NCT06493370
Drug: Intravenous ascorbic acid/vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose escalation regimen will be initiated for each participant at a single dose of 25 g, titrated to up target peak plasma concentration. Once established, IVC will be administered intravenously 2 times per week for the remaining cycles
Trial: NCT05029973
Drug: HAIC
RxNorm normalized name: Hepatic Arterial Infusion Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
Trial: NCT06215430
Drug: Caffeine Tablet
RxNorm normalized name: Caffeine Tablets
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05684523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00934258
Drug: rosuvastatin,fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg once daily Rosuvastatin 5 mg + SFC fenofibrate 80 mg
Trial: NCT05351047
Drug: AZD2373 subcutaneous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized subjects will receive multiple ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5).
Trial: NCT05351047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized subjects will receive a multiple ascending dose of placebo (saline solution) by SC injection.
Trial: NCT06305637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
Trial: NCT04518280
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 1000mg/m2 bid d1-14 q3w
Trial: NCT04746105
Drug: TS-142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received single-dose of 10 mg of TS-142 (oral tablet)
Trial: NCT04746105
Drug: Dose-matched Placebo to TS-142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received single-dose matched placebo to TS-142 (oral tablet)
Trial: NCT05535933
Drug: HMPL-523(300mg PO QD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMPL-523(300mg PO QD)
Trial: NCT05535933
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo(300mg PO QD)
Trial: NCT06166381
Drug: Parenteral Antibacterial Agents
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral antibiotic (ceftriaxone) 1 g to be given in 3 doses, at induction of anesthesia, 12 hours postoperative, and 24 hours postoperative.
Trial: NCT05915286
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
Trial: NCT05008835
Drug: ACP-044 Dose A
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dose of ACP-044 Dose A
Trial: NCT05008835
Drug: ACP-044 Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of ACP-044 Dose B
Trial: NCT05008835
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05655091
Drug: FLU or CZO as continuous infusion
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion FLU or CZO coupled with real-time TDM and subsequent dose adjustment. A loading dose will be administered prior to the first continuous infusion. The loading dose (maximum of 2g as licensed according to the SmPC) and the dose of the continuous infusion will be calculated according to a pharmacokinetic model taking into account patient's characteristics (e.g. age, sex) and the measured drug concentration. The maximum daily dose of FLU and CZO will not exceed 12 grams per day according to the SmPC.
Trial: NCT06575751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this Arm will take a medically inert placebo. Participants will take medication by mouth with food in the morning and evening.
Trial: NCT06458686
Drug: Vit D
RxNorm normalized name: Tri-Vit Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D is a fat soluble vitamin used for the treatment of many diseases.
Trial: NCT06622070
Drug: SPY002-072
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental
Trial: NCT06333808
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally without regard to food
Trial: NCT06333808
Drug: Placebo to match B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally without regard to food
Trial: NCT06333808
Drug: Placebo to match BIC/LEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally without regard to food
Trial: NCT06105684
Drug: Capecitabine Pill
RxNorm normalized name: capecitabine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be given once per day by mouth
Trial: NCT04817241
Drug: Decitabine and Cedazuridine
RxNorm normalized name: cedazuridine / decitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05007782
Drug: Denikitug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Intravenously
Trial: NCT06541613
Drug: local anesthetic injection (bupivacaine)
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The in-plane technique with a 22G, 80 mm block needle is used to inject 30 ml of 0.25% bupivacaine into the external oblique intercostal plane on both sides.
Trial: NCT06511063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo.
Trial: NCT06144086
Drug: Foscenvivint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous (IV) infusion over 3-4 hours
Trial: NCT06197295
Drug: Combination pharmacotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5mg and Mirabegron 25mg
Trial: NCT05411133
Drug: Cabotamig (ARB202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabotamig (ARB202), Atezolizumab
Trial: NCT05780723
Drug: Treatment group: Rectal instillation of QHQYP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QHQYP is decocted in water, with a dose of 100ml each time, and rectal drip before going to bed, once a night, for 8 weeks.
Trial: NCT05890001
Drug: BLI5100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take BLI5100 once daily, orally, for up to 29 weeks.
Trial: NCT06336798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will take a placebo PO daily
Trial: NCT06553027
Drug: CVN424 75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 75 mg CVN424 tablet once daily.
Trial: NCT06553027
Drug: CVN424 150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 150 mg CVN424 tablet once daily.
Trial: NCT06553027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo tablet once daily.
Trial: NCT05418088
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05168748
Drug: IMJ995 single agent
RxNorm normalized name: MISCELLANEOUS AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous administration of IMJ995
Trial: NCT05307731
Drug: guideline-based treatment for DM
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guideline-based treatment for DM
Trial: NCT05940883
Drug: Y-2 Sublingual Tablet
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one Y-2 sublingual tablet sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.
Trial: NCT05940883
Drug: Y-2 Sublingual Tablet
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive two Y-2 sublingual tablets sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.
Trial: NCT05940883
Drug: Y-2 Sublingual Tablet
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition A, Day 6 with condition B and Day 11 with condition C.
Trial: NCT05940883
Drug: Y-2 Sublingual Tablet
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition B, Day 6 with condition C and Day 11 with condition A.
Trial: NCT05940883
Drug: Y-2 Sublingual Tablet
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition C, Day 6 with condition A and Day 11 with condition B.
Trial: NCT05940883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, sublingually, single and multiple ascending dosing in group 1 and 2 subjects.
Trial: NCT06270030
Drug: Placebo (Vehicle) ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
Trial: NCT05880563
Drug: [18F]-RoSMA-18-d6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]-RoSMA-18-d6 will be administered intravenously by a bolus injection followed by a subsequent PET/CT-scan of the brain and the spine
Trial: NCT06360796
Drug: [(14)C]ADC189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject take a single oral dose of about 45 mg (about 100 μCi) \[(14)C\]ADC189 on Day 1 of the study, and be observed by 504 hours.
Trial: NCT06217822
Drug: 225Ac-PSMA-Trillium (BAY3563254)
RxNorm normalized name: TRILLIUM CHLOROPETALUM WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous slow injection on Day 1 of a 6 week treatment cycle.
Trial: NCT05574166
Drug: SP-8356
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP-8356 demonstrates anti-atherosclerotic and anti-ischaemic activity as a novel CD147 inhibitor.
Trial: NCT05574166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for SP-8356 powder
Trial: NCT05282277
Drug: Transdermal Estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.
Trial: NCT05282277
Drug: Matching Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks
Trial: NCT06387082
Drug: HMPL-506
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMPL-506 will be administered orally in 28-day cycles, until disease progression/relapse , death, intolerable toxicity, receipt of another anti-tumor therapy (including HSCT), failure to further benefit , patient withdrawal, loss to follow-up or end of the study, whichever comes first.
Trial: NCT05394142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator arm with placebo
Trial: NCT05394142
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone 50 mg/day
Trial: NCT05619302
Drug: [68Ga]CBP8 PET/MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous cardiac PET/MRI images will be obtained following injection of \[68Ga\]CBP8
Trial: NCT05064202
Drug: Inotropes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone, Dobutamine, Dopamine, Milrinone
Trial: NCT05386823
Drug: HF1K16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HF1K16 for Injection doses will be calculated based on subject weight measured at admission, and diluted in sterile saline (0.9% sodium chloride). Doses will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
Trial: NCT05386823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be sterile saline (0.9% sodium chloride) which will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
Trial: NCT05170009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo at baseline, day 4, and day 7.
Trial: NCT06001385
Drug: Post-Transplant Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours.~First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant.
Trial: NCT06001385
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV pre-transplant as part of conditioning regimen
Trial: NCT05355402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olezarsen-matching placebo will be administered once every 4 weeks by SC injection for up to 49 weeks.
Trial: NCT06255834
Drug: IPG11406
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 0.5 mg, 10 mg and 40 mg Storage：15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 or placebo tablets are orally administered once on Day 1 (Part A) or daily for 10 days from Day 1 to Day 10 (Part B) in a fasted state. Oral doses will be administered with 240 ml of water. Tablets should not be chewed or crushed.~Participants in the FE Cohort will receive a second single dose of IPG11406 following a standardized high fat meal upon ≥4 days washout period after the first dose.~IPG11406 Placebo Placebo tablets: tablets identical to IPG11406 tablets
Trial: NCT06375733
Drug: GFH009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered as an IV infusion at the dose levels 75mg, 60mg, and/or 100mg QW.
Trial: NCT06375733
Drug: GFH009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the RP2D of GFH009 defined in the preliminary phase 1b trial with the same schedule as in the phase Ib.
Trial: NCT05285683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral pill
Trial: NCT06181760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of matching placebo capsules
Trial: NCT04676763
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive normal saline as Negative control
Trial: NCT05138822
Drug: GSK3882347
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3882347 will be administered on each dosing day.
Trial: NCT05138822
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching study drug (GSK3882347) or Nitrofurantoin will be administered on each dosing day.
Trial: NCT06179069
Drug: ZL-1310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: ZL-1310
Trial: NCT05639933
Drug: HT-001 2% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel, 2% active
Trial: NCT06197425
Drug: FOLFIRI cures
RxNorm normalized name: Cocci-Cure C for Calves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Irinotecan 180 mg/m2, leucovorine 400mg/m2, 5FU bolus 400 mg/m2, 5FU continuous infusion 2400 mg/m2) every 14 days for 6 months or until disease progression on imaging
Trial: NCT06197425
Drug: Trifluridine cures
RxNorm normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trifluridine tipiracil 35 mg/m2 bid during 5 days/w on week 1 and 2 every 4 weeks, for 6 months or until disease progression on imaging
Trial: NCT05285878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg daily
Trial: NCT05048056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection every 2 weeks for 16 weeks then Crossover to AK120 Regimen 1
Trial: NCT06269978
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given via IP infusion
Trial: NCT04929223
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.
Trial: NCT04929223
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) IV will be administered as per schedule specified in the respective arm.
Trial: NCT05757310
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO and IV
Trial: NCT05296356
Drug: OSU6162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSU6162
Trial: NCT05878093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for subcutaneous injection
Trial: NCT04830137
Drug: NX-2127
RxNorm normalized name: Replesta NX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral NX-2127
Trial: NCT05554211
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is a topical application of 50 cc's of 3% tranexamic acid. In the operating room, control normal saline (NS) irrigation will be administered following gentamicin irrigation. NS irrigation solution will be the last irrigation used prior to wound closure in order to assure maximum benefit derived from TxA administration, if any.
Trial: NCT05797753
Drug: SAR443820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet by oral administration
Trial: NCT05797753
Drug: SAR443820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule by oral administration
Trial: NCT05797753
Drug: Erythromycin ethyl succinate
RxNorm normalized name: Erythromycin ethyl succinate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet by oral administration
Trial: NCT06504862
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin
Trial: NCT05135390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three times per week